Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | ESR1 | P03372 | 11/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9371 | 1.00 | BLM (0.67) | BLMESR1ESR2NR1I2KMT2A | |
| SCHEMBL707840 | 0.88 | BLM (0.87) | BLMESR1ESR2NR1I2KMT2A | |
| SCHEMBL707841 | 0.88 | BLM (0.87) | BLMESR1ESR2NR1I2KMT2A | |
| Diethylstilbestrol SCHEMBL9373 | 0.86 | ESR1 (0.67) | BLMESR1ESR2NR1I2KMT2A | |
| SCHEMBL329314 | 0.84 | PTPN1 (0.44) | BLMESR1ESR2KMT2ASMN1; SMN2 | |
| Diethylstilbestrol SCHEMBL21805900 | 0.84 | ESR1 (0.55) | BLMESR1ESR2NR1I2KMT2A | |
| SCHEMBL9858001 | 0.82 | ESR1 (0.67) | ESR1ESR2NR1I2KMT2AHIF1A | |
| SCHEMBL4254509 | 0.81 | ESR1 (0.54) | BLMESR1ESR2KMT2ASMN1; SMN2 | |
| Diethylstilbestrol Diphosphate SCHEMBL9370 | 0.81 | BLM (1.00) | BLMESR1ESR2NR1I2KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL6231203 | 0.81 | BLM (1.00) | BLMESR1ESR2NR1I2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694915-A1 | TREATMENT OF HAEMATOLOGICAL CANCER | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| EP-4694914-A1 | INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| US-12527836-B2 | Gla domains as targeting agents | GLAdiator Biosciences, Inc. (US) | 2026-01-20 | — | — | US | claimed |
| WO-2024213640-A1 | INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT | STERLING IP PTE. LTD. (SG) | 2024-10-17 | — | — | WO | claimed |
| WO-2024213648-A1 | TREATMENT OF HAEMATOLOGICAL CANCER | STERLING IP PTE. LTD. (SG) | 2024-10-17 | — | — | WO | claimed |
| EP-3524618-B1 | GLA DOMAINS AS TARGETING AGENTS | GLADIATOR BIOSCIENCES INC (US) | 2023-03-08 | — | — | EP | claimed |
| EP-4694914-A1 | INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | disclosed |
| EP-4694915-A1 | TREATMENT OF HAEMATOLOGICAL CANCER | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | disclosed |
| US-12527836-B2 | Gla domains as targeting agents | GLAdiator Biosciences, Inc. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| WO-2024213640-A1 | INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT | STERLING IP PTE. LTD. (SG) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024213648-A1 | TREATMENT OF HAEMATOLOGICAL CANCER | STERLING IP PTE. LTD. (SG) | 2024-10-17 | — | — | WO | disclosed |
| US-11981723-B2 | Method of targeting exosomes | GLAdiator Biosciences, Inc. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240145031-A1 | Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators | Precision Medicine Lab (NL) | 2024-05-02 | — | — | US | disclosed |
| EP-4174082-A1 | GLA DOMAINS AS TARGETING AGENTS | GLAdiator Biosciences, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3524617-B1 | GLA DOMAINS AS THERAPEUTIC AGENTS | GLADIATOR BIOSCIENCES INC (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3524618-B1 | GLA DOMAINS AS TARGETING AGENTS | GLADIATOR BIOSCIENCES INC (US) | 2023-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527836-B2 | Gla domains as targeting agents | GHITM, PTDSS1, PTDSS2 | BLM 4575/4885ESR1 737/4885ESR2 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.